Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

This phase IV trial studies whether there is a relationship between how a patient is positioned while receiving bacillus Calmette Guerin (BCG) within the bladder (intravesical) and how long BCG stays in the bladder (dwell time) to improve the treatment of non-muscle invasive bladder cancer. For the past 40 years, intravesical BCG has been used for the treatment of non-muscle invasive bladder cancer. An important factor for BCG treatment is the dwell time, which is the period of time a patient can hold the BCG medication in the bladder after it has been given. Normally, patients are instructed

Trial Details

NCT ID
NCT07474519
Phase
PHASE4
Sponsor
Ohio State University Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Bladder Cancer
Interventions
  • Accelerometry
  • BCG Solution
  • Electronic Health Record Review
  • Patient Discharge
  • Survey Administration
Locations (sample)
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Patient with intermediate or high risk NMIBC opting for intravesical induction BCG
  • Has not initiated induction therapy
  • Able to remain in supine position for two hours. (Head may be raised on up to two pillows)
  • Able to remain in a sitting position for two hours

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Bladder Cancer Trials on Trialify →